Back to News
Market Impact: 0.3
Evaxion Reports Durable Three-Year Responses With EVX-01 In Advanced Melanoma
Source: Nasdaq
Healthcare & Biotech
In a Phase 2 study of advanced melanoma, patients who responded to Evaxion’s personalized cancer vaccine EVX-01 maintained their clinical responses through three years of follow-up. The article excerpt reports no tumor progression among an unspecified group; it provides no response rate or further study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
EVAX0.75
More News
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover
- Goldman says play defense with these stocks if you're worried about the AI bull failing
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs
- AI Tools for CFA Charterholders: An Evidence Standard